CLEC6A (C-type lectin domain containing 6A) is a calcium-dependent pattern recognition receptor of the innate immune system that primarily functions in antifungal immunity and inflammatory signaling. The protein specifically recognizes and binds alpha-mannans on Candida albicans hyphae, triggering downstream signaling through ITAM phosphorylation, SYK activation, CARD9, and NF-κB pathways to promote antigen-presenting cell maturation and T-helper 1/17 responses [UniProt]. CLEC6A operates as part of the C-type lectin receptor signaling pathway, which has been implicated in cancer cell differentiation processes 1. In clinical contexts, CLEC6A expression serves as a prognostic biomarker across multiple diseases. Higher CLEC6A expression correlates with better survival outcomes in breast cancer patients 2 and is incorporated into prognostic models for gastric cancer 3 and melanoma 4. The protein also shows associations with cardiovascular disease risk in HIV patients 5 and COVID-19 severity prediction 6. Additionally, genetic variants in CLEC6A (rs12099687) are associated with aspergillosis susceptibility in pediatric hematological malignancy patients 7, and the CCR2-CLEC6A axis appears involved in acute myeloid leukemia pathogenesis 8.